News & Events – Ysios Capital

20 Nov 2024

Ysios Capital ESG Report

Upcoming events

AI in Drug Discovery and Biomedicine
31 March 2025
Barcelona
Redefining Early Stage of Investment (RESI)
1 April 2025
Barcelona
Life Sciences Conference – Van Lanschot Kempen
2 - 3 April 2025
Amsterdam
Swisss Biotech Day
5 - 6 May 2025
Basel

Type:

Year:

12 Nov 2014

TiGenix completes patient recruitment for the European Phase III trial of Cx601 ahead of schedule

Leuven (BELGIUM) – 12 November, 2014 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that it has completed the patient recruitment for its Phase III trial of Cx601 in Europe for the treatment of complex perianal fistulas in Crohn’s patients.

23 Oct 2014

MedLumics Introduces NITID Skin Imaging System at EADV

MADRID – Oct. 23, 2014 – MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, debuted its NITIDTM skin imaging system at the 23rd Annual European Academy of Dermatology and Venereology Congress in Amsterdam.

07 Oct 2014

CVRx® Announces First Successful Barostim Heart Failure Commercial Implants in Europe

Minneapolis – October 7, 2014 – CVRx, Inc., a private medical device company, announced today the first 10 heart failure patients treated with the Barostim neo System™ under CE Mark approval.

30 Sep 2014

CVRx® Receives CE Mark Approval of the Barostim neo System™ for the Treatment of Heart Failure

Minneapolis – September 29, 2014 – CVRx, Inc., a private medical device company, announced today it received CE Mark approval from the National Standards Authority of Ireland (NSAI) of the Barostim neo System™ for the treatment of heart failure.

22 Sep 2014

CVRx® Secures $15 Million Growth Capital Facility from Silicon Valley Bank

Minneapolis – September 22, 2014 – CVRx, Inc., a private medical device company, announced today it secured a $15 million growth capital debt facility from Silicon Valley Bank.

16 Sep 2014

AM-Pharma closes €12.2m financing round

Ysios Capital joins Am Pharma's 12.2 million euro financing.

08 Sep 2014

European Medicines Agency accepts TiGenix Paediatric Investigation Plan for Cx601

Leuven (BELGIUM) – 8 September, 2014 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, announced today that the Paediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Paediatric Investigation Plan (PIP) for Cx601, a locally injected stem cell product in Phase III of clinical development for the treatment of complex perianal fistulas in patients with Crohn´s disease.

01 Sep 2014

TiGenix appoints Chief Medical Officer and Vice President Medical Affairs and New Product Commercialisation

Leuven (BELGIUM) – 1 September, 2014 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, announced today that it has appointed Dr Marie Paule Richard as the Company’s Chief Medical Officer, and Dr Mary Carmen Diez as its Vice President Medical Affairs and New Product Commercialisation.

28 Aug 2014

TiGenix Business and Financial Update for the First Half of 2014

Leuven, Belgium – 26 August, 2014 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, issued an update on business and financial progress in the first half of this year today.

01 Jul 2014

European Medicines Agency renews Marketing Authorisation for ChondroCelect

Leuven (BELGIUM) – 1 July, 2014 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that the Committee for Medicinal Products for Human Use (CHMP) has renewed for an additional five years its marketing authorisation for ChondroCelect in all of the 31 countries of the European Union (EU) and European Economic Area (EEA).